

Animal Medicines Australia ABN 76 116 848 344 | ACN 116 848 344 18 National Circuit Barton ACT 2600, Australia P: +61 2 6257 9022 animalmedicinesaustralia.org.au

12 October 2021

Australia-UK FTA Coordinator Regional Trade Agreements Division Department of Foreign Affairs and Trade RG Casey Building, John McEwen Crescent Barton ACT 0221

Submitted by email only: ukfta@dfat.gov.au

Re: Australia-United Kingdom Free Trade Agreement negotiations

Thank you for the opportunity to provide a submission on the Australia-United Kingdom Free Trade Agreement negotiations.

Animal Medicines Australia (AMA) is the peak industry body representing the leaders of the animal medicines industry in Australia. Our members companies are the innovators, manufacturers, formulators and registrants of a broad range of veterinary medicine products to protect and treat animal illness, disease and injury, and support animal welfare across the livestock, equine and companion animal sectors. AMA members range from local businesses to the local divisions of global companies and includes companies who manufacture in Australia for global export markets. AMA members represent more than 90% of Australian sales of registered veterinary products.

Veterinary medicinal products are essential tools for veterinarians and farmers to promote and protect animal health and welfare, food safety, public health, environmental health, agricultural production, sustainability, innovation and investment. Animal health is the foundation of animal welfare and supports the sustainable production of safe, high-quality food and fibre derived from animals.

In support of these trade negotiations, AMA have engaged with our equivalent organisation in the United Kingdom, the National Office for Animal Health (NOAH), to develop shared Free Trade

Agreement Principles to support a stronger Australia-UK trade relationship. These principles are attached to this letter.

These principles support the <u>Australia-UK Free Trade Agreement: agreement in principle</u> (<u>Australia-UK FTA negotiations: agreement in principle | Australian Government Department of Foreign Affairs and Trade (dfat.gov.au)</u>). In particular, AMA and NOAH support measures that will promote trade, facilitate market access, increase investment and innovation, support animal welfare, address antimicrobial resistance, encourage good regulatory practice, harmonise regulatory requirements, reduce technical barriers to trade, promote adoption of international science-based regulatory standards and requirements, and protect globally integrated manufacture and supply chains.

In the consideration of veterinary medicinal products in the FTA, AMA wishes to note that these principles should be considered to apply to a range of products relevant to animal health, including:

- Finished medicinal products for veterinary use, including biological and immunobiological products;
- Active pharmaceutical ingredients, additives, intermediates, excipients and other components used in the manufacture and administration of veterinary medicinal products;
- Investigational and diagnostic veterinary medicinal products, including sensors and identification tools; and
- Animal health products that may not be defined as veterinary medicines, such as feed additives, devices, diagnostics and biocides.

AMA and NOAH are pleased to provide these principles for your consideration during negotiations for the new Australia-UK FTA. We would welcome an opportunity to discuss these with you.

If we can provide any further information, please feel free to contact me.

Yours sincerely,

Ben Stapley

Executive Director

Attachment: Shared Free Trade Agreement Principles for a Stronger AUS-UK Trade Relationship